FGFR inhibitors with reported anti-myeloma activity are shown in Table 1, including two experimental FGFR3 inhibitors, SU5402 and PD173074, that have demonstrated activity against t(4;14)-positive myeloma cell lines [50]. This evidence concerns the gene FGFR3 and plasma cell myeloma.